



PRESS RELEASE, October 7, 2019

Immunotherapy as effective in animal model as antibiotics for urinary tract infections

SelectImmune Pharma has today presented preliminary results of a new preclinical study that found that the company's immunotherapy of urinary tract infections is as effective in an animal model as antibiotics. An initial examination of the data indicates that the immunomodulatory treatment produced a healing response in the infection that was entirely comparable with antibiotics. The findings strengthen the company's strategic efforts to initiate clinical treatment studies, mainly focused on urinary tract infections.

SelectImmune Pharma AB is developing new immunotherapies against common infectious diseases. The goal is to complement or replace antibiotics. This concept is based on new knowledge about how the immune system works in detail, to strengthen the defensive aspects and block the damaging aspects of the immune response. Researchers at Lund University, who founded the company, showed that immunomodulatory treatment can heal infections without antibiotics in animal models that emulate infections in humans.

In a new study of urinary tract infections in animal models, researchers associated with SelectImmune found that immunotherapy is as effective as antibiotics. Two treatment study groups were treated, either with antibiotics or immunotherapy and were compared with an untreated control group. An initial examination of the data indicates that the immunomodulatory treatment produced a healing response in the infection that was entirely comparable with antibiotics. The treatment reduced inflammation in the infected tissue and effectively killed bacteria. No similar healing was observed in the untreated control group.

Laboratory analysis of the material is continuing, and the intention is to publish data in a leading scientific journal as soon as possible.

These results strengthen the company's strategic work to begin clinical treatment studies, primarily focused on recurring urinary tract infections.

For more information, contact:

Catharina Svanborg
Chairman of the Board, SelectImmune Pharma AB
Telephone +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se

Fredrik Herslow
CEO, SelectImmune Pharma AB
Tel: +46 705 91 15 44
E-mail: fredrik.herslow@selectImmune.com

Erik Sturegård
Chief Medical Officer, SelectImmune Pharma AB
Tel: +46 703 42 14 69
E-mail: erik.sturegard@med.lu.se

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The Company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

This information is inside information that SelectImmune AB is required to publish under the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on October 7, 2019.